Literature DB >> 3552018

Presence and possible significance of immunohistochemically demonstrable prolactin in breast apocrine metaplasia.

S Kumar, R E Mansel, B Jasani.   

Abstract

Paraffin wax embedded formalin-fixed benign breast disease tissue taken from 17 patients (15 with microcystic disease and 2 with fibroadenoma) was studied for the presence of tissue bound prolactin using a rabbit antiserum against human prolactin applied in conjunction with a highly sensitive modified version of the dinitrophenyl (DNP)-hapten sandwich staining (DHSS) procedure. Sections taken from 14 of the 15 cases showing apocrine cystic changes exhibited strong prolactin staining restricted to the cytoplasm of metaplastic apocrine cells lining the cysts. Normal lobules and ducts and blunt duct proliferations were all negative, as were also the two cases of fibroadenoma. In contrast 6 out of 8 cases of breast cancer examined showed heterogenously distributed cytoplasmic staining in the cancer cells. Maximal prolactin staining in the apocrine cells was observed at antiserum dilutions as high as 1:60,000. This compared favourably with a 1:120,000 dilution that gave maximal levels of staining in the prolactotrophs present in serial sections taken from formalin fixed paraffin wax embedded post mortem human anterior pituitaries. In both types of tissues the specific staining was abolished by pre-absorption of the antiserum with human prolactin (10 micrograms ml-1). No staining was observed when the anti-prolactin serum was either omitted or substituted with DNP-labelled normal rabbit serum. Apocrine metaplasia in cystic disease of the breast has recently been found to be associated with an increased breast cancer risk. The strong and selective presence of immunohistochemically demonstrable prolactin in the metaplastic cells may be of significance in view of the hormone's known growth stimulating effect on the breast epithelium.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552018      PMCID: PMC2001745          DOI: 10.1038/bjc.1987.60

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Immunoreactive prolactin in epithelial cells of normal and cancerous human breast and prostate detected by the unlabeled antibody peroxidase-antiperoxidase method.

Authors:  D M Purnell; E A Hillman; B M Heatfield; B F Trump
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

Review 2.  Mechanism of action of prolactin in the control of mammary gland function.

Authors:  R P Shiu; H G Friesen
Journal:  Annu Rev Physiol       Date:  1980       Impact factor: 19.318

3.  Use of monoclonal antihapten antibodies for immunolocalisation of tissue antigens.

Authors:  B Jasani; D W Thomas; E D Williams
Journal:  J Clin Pathol       Date:  1981-09       Impact factor: 3.411

4.  Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease.

Authors:  S Kumar; R E Mansel; L E Hughes; J S Woodhead; C A Edwards; M F Scanlon; R G Newcombe
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

5.  Prolactin and prolactin binding sites in human breast cancer cells.

Authors:  E Marchetti; A P Rimondi; P Querzoli; G Fabris; I Nenci
Journal:  Prog Clin Biol Res       Date:  1984

6.  The relationship of cyst type to risk factors for breast cancer and the subsequent development of breast cancer in patients with breast cystic disease.

Authors:  J M Dixon; A B Lumsden; W R Miller
Journal:  Eur J Cancer Clin Oncol       Date:  1985-09

7.  Risk of breast cancer in women with history of benign disease of the breast.

Authors:  M M Roberts; V Jones; R A Elton; R W Fortt; S Williams; I H Gravelle
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

8.  Non-deleterious dinitrophenyl (DNP) hapten labelling of antibody protein. Preparation and properties of some short-chain DNP imidoesters.

Authors:  M J Hewlins; I Weeks; B Jasani
Journal:  J Immunol Methods       Date:  1984-05-11       Impact factor: 2.303

9.  The use of vimentin antibodies in the diagnosis of malignant mesothelioma.

Authors:  B Jasani; R E Edwards; N D Thomas; A R Gibbs
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

View more
  4 in total

1.  Oestrogen-regulated 24-kDa protein--a marker for breast carcinoma in benign breast tissue.

Authors:  S P Courtney; S Williams; R E Mansel
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Can monoclonal antibody staining by 323/A3 and Ca1 of benign breast biopsies predict the development of breast cancer?

Authors:  S P Courtney; S Williams; R E Mansel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia.

Authors:  W Tschugguel; W Knogler; K Czerwenka; M Mildner; W Weninger; R Zeillinger; J C Huber
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

Review 4.  A Review on Mammary Tumors in Rabbits: Translation of Pathology into Medical Care.

Authors:  Sandra Schöniger; Sophie Degner; Bharat Jasani; Heinz-Adolf Schoon
Journal:  Animals (Basel)       Date:  2019-10-02       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.